QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:ECYT

Endocyte (ECYT) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)
Free ECYT Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$23.99
▼
$23.99
50-Day Range
N/A
52-Week Range
$2.81
▼
$24.00
Volume
N/A
Average Volume
2.12 million shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
ECYT stock logo

About Endocyte Stock (NASDAQ:ECYT)

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

ECYT Stock News Headlines

February 16, 2024 | investing.com
Telix Pharmaceuticals Ltd (TLX)
January 3, 2024 | fool.com.au
'The most exciting company in Australia': The ASX stock up 179% in 6 months
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
May 17, 2023 | thestreet.com
The Endocyte Bear Thesis: Why March Will be a Bad Month
January 5, 2023 | thestreet.com
Why Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading Today
September 20, 2022 | finance.yahoo.com
Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo Finance
June 6, 2022 | globenewswire.com
Purdue University impacting lives: successfully delivering innovations to the public - GlobeNewswire
May 23, 2022 | globenewswire.com
Global Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswire
April 19, 2024 | Behind the Markets (Ad)
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
May 20, 2022 | benzinga.com
Cortexyme Appoints Dr. Philip Low to Its Board of Directors - Benzinga - Benzinga
May 20, 2022 | streetinsider.com
Cortexyme (CRTX) Appoints Philip Low to Its Board - StreetInsider.com
May 3, 2022 | nasdaq.com
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List? - Nasdaq
April 25, 2022 | seekingalpha.com
Clovis: Shifting Toward Nuclear Medicine - Seeking Alpha
April 14, 2022 | globenewswire.com
Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Research Inc - GlobeNewswire
January 31, 2022 | globenewswire.com
Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight - GlobeNewswire
January 27, 2022 | finance.yahoo.com
Global Oncology Radiopharmaceuticals Market to Surpass US$ 5,206.8 Million by 2028, Says Coherent Market Insights (CMI) - Yahoo Finance
December 19, 2021 | proactiveinvestors.com.au
Radiopharm Theranostics enhances management team skillset with three key appointments - Proactive Investors Australia
November 2, 2021 | finance.yahoo.com
Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer - Yahoo Finance
November 2, 2021 | streetinsider.com
Fusion Pharmaceuticals Inc. (FUSN) Appoints Christopher Leamon as Chief Scientific Officer - StreetInsider.com
September 20, 2021 | streetinsider.com
Mirati Therapeutics (MRTX) Appoints David Meek as CEO - StreetInsider.com
August 16, 2021 | afr.com
Telix Pharma is on the cusp of first US FDA approval - The Australian Financial Review
See More Headlines
Receive ECYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2018
Today
4/19/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ECYT
CUSIP
29269A10
CIK
1235007
Web
www.endocyte.com
Phone
765-463-7175
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-55,060,000.00
Net Margins
-32,296.09%
Pretax Margin
N/A
Return on Equity
-21.19%
Return on Assets
-20.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
45.80
Quick Ratio
45.80

Sales & Book Value

Annual Sales
$70,000.00
Price / Sales
28,133.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.99 per share
Price / Book
12.06

Miscellaneous

Outstanding Shares
82,090,000
Free Float
N/A
Market Cap
$1.97 billion
Optionable
Optionable
Beta
-0.01
20 Stocks to Sell Now Cover
20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Michael A. Sherman (Age 52)
    CEO, Pres & Director
  • Mr. Michael T. Andriole (Age 45)
    Chief Financial Officer
  • Dr. Alison A. Armour (Age 54)
    Chief Medical Officer
  • Dr. Christopher P. Leamon (Age 52)
    VP of R&D
  • Dr. Philip S. Low (Age 70)
    Co-Founder, Chief Science Officer & Director

Key Competitors

View All Competitors

ECYT Stock Analysis - Frequently Asked Questions

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) released its quarterly earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company earned $0.09 million during the quarter, compared to analyst estimates of $0.02 million. Endocyte had a negative trailing twelve-month return on equity of 21.19% and a negative net margin of 32,296.09%.

What other stocks do shareholders of Endocyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Celldex Therapeutics (CLDX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Bausch Health Companies (BHC) and Inovio Pharmaceuticals (INO).

This page (NASDAQ:ECYT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
SHOCKING Crypto Leak…
Crypto 101 Media
Man Who Predicted 2008: “This Will be Worse.”
Altimetry
Fed launches fourth dollar overhaul
Stansberry Research